Eduardo López Bran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Eduardo López Bran has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Conde‐Taboada
Dermatology Department Hospital Clínico San Carlos Madrid Spain
3 shared publications - Elena González-Guerra
Departamento de Dermatología, Hospital Clínico San Carlos, Madrid, Spain
3 shared publications - José Antonio Cortés Toro
Department of Pathological Anatomy, Hospital Clinico Universitario San Carlos, Madrid, Spain
2 shared publications - Pedro Pérez-Segura
Medical Oncology Department, Hospital Clínico San Carlos (HCSC), Instituto de Investigación Sanitaria San Carlos (IdISSC), 28040 Madrid, Spain
2 shared publications Alberto Romero-Maté
Dermatology Department, Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain
1 shared publication- Ana Sánchez-Fructuoso
Hospital Clínico San Carlos and Universidad Complutense de Madrid, Madrid, Spain
1 shared publication
Latest Publications
- Open Access
- 1 November 2026
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 19, 1-18
Real-World Use of Baricitinib for Severe Alopecia Areata in Spain: The ROSE-S Observational Study
Purpose: Alopecia areata (AA) is an autoimmune disorder characterized by non-scarring hair loss. Baricitinib is the first oral Janus kinase inhibitor approved for severe AA in adults. This study aimed to describe persistence, treatment patterns, effectiveness and patient satisfaction in adults receiving baricitinib in routine clinical practice in Spain. Methods: A multicenter, retrospective observational cohort study with a cross-sectional PRO assessment was performed in adults with severe AA (SALT score ≥ 50) treated with baricitinib at 15 Spanish hospitals from June 2022 and with at least 36 weeks of follow-up, regardless of whether they remained on treatment. Sociodemographic, clinical, and treatment data were collected. Effectiveness was assessed using SALT score at treatment initiation and at 12, 24, 36, and 52 weeks, and the percentage of patients with SALT≤ 20. A cross-sectional visit (≥ 36 weeks since baricitinib initiation) collected the Treatment Satisfaction Questionnaire for Medication (TSQM), four ad-hoc questions regarding treatment satisfaction in specific areas (body hair, nails, beard, eyebrows/eyelashes), and the Scalp Hair Assessment PRO™. Analyses, all descriptive, summarized outcomes overall and by affected area, with persistence assessed via Kaplan-Meier. Results: 109 patients (67.9% females) were included in the study, with a mean (standard deviation [SD]) AA duration of 11.1 (11.0) years. The mean (SD) baseline SALT score was 81.1 (18.7) and 75.0% started with baricitinib monotherapy. At week 52, 91.8% continued treatment and 71.1% achieved a SALT≤ 20. Mean (SD) treatment satisfaction was 341.0 (51.4) out of 400 points on the TSQM. In subpopulations affected in specific areas, persistence rates exceeded 87%, at least 55% achieved SALT≤ 20 at week 52, and mean satisfaction score was above 320. Conclusion: In this real-world cohort in Spain, baricitinib use was associated with high treatment persistence and satisfaction, together with improved SALT scores in adults with severe AA, including those with involvement of body hair, nails, beard, and eyebrows/eyelashes. Plain Language Summary: Alopecia areata (AA) is a common autoimmune disease. It makes hair fall out in patches, without leaving scars. It affects men and women of all ages and often causes emotional distress and a lower quality of life. We studied 109 adults with severe AA who were treated with baricitinib, a tablet approved for this condition, at 15 hospitals in Spain. For every patient, at least 36 weeks had passed since starting baricitinib, whether or not they were still taking it when we collected the data. We measured how many patients stayed on treatment, how their hair regrew, and how satisfied they felt, at several points up to 52 weeks. By week 52, most patients were still taking baricitinib, and their scalp hair loss had improved significantly. Patients felt satisfied with the treatment, and almost 80% said their hair loss had improved. Even so, in everyday clinical practice, baricitinib use was associated with high treatment persistence, patient-reported satisfaction, and improvement in patients’ scalp hair loss scores and perception in adults with severe AA, including those with involvement of body hair, nails, beard, and eyebrows/eyelashes. These findings could help guide clinical decisions and improve the management of severe AA. Infographic summarizing population, methodology and findings for baricitinib in severe alopecia areata. Population: Adults with severe alopecia areata (AA) with SALT greater than or equal to 50, treated with baricitinib since June 2022 and with at least 36 weeks of follow-up. Methodology: Multicenter, retrospective observational cohort study with a cross-sectional PRO assessment conducted in 15 Spanish hospitals. A timeline shows a patient recruitment period from October 2024 to February 2025. The index date corresponded to baricitinib initiation. Retrospective data collection included AA diagnosis, previous AA treatments and clinical characteristics. Follow-up assessments, when available, were conducted at Weeks 12, 24, 36, and 52 and included sociodemographic and clinical characteristics, SALT, and AA treatment patterns. At the end of follow-up (greater than or equal to 36 weeks after baricitinib initiation), a cross-sectional assessment visit includes SALT and AA treatment patterns, together with patient-reported outcomes: TSQM, ad hoc treatment satisfaction in specific areas, and patient-reported scalp hair assessment. Findings: In Spanish routine clinical practice, baricitinib showed high treatment persistence (91.8 percent persistence at Week 52), effectiveness (71.1 percent achieved SALT less than or equal to 20 at Week 52), and high patient-reported satisfaction (341 out of 400 points on the TSQM) together with improved perceived scalp hair loss (78.5 percent reported improvement). These results were also observed in patients with involvement of special areas, including body hair, nails, beard hair, and eyebrows or eyelashes.Infographic on baricitinib for severe alopecia areata: population, methodology and findings.
- 1 November 2026
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 19, 1-18
Open AccessReal-World Use of Baricitinib for Severe Alopecia Areata in Spain: The ROSE-S Observational Study
Purpose: Alopecia areata (AA) is an autoimmune disorder characterized by non-scarring hair loss. Baricitinib is the first oral Janus kinase inhibitor approved for severe AA in adults. This study aimed to describe persistence, treatment patterns, effectiveness and patient satisfaction in adults receiving baricitinib in routine clinical practice in Spain. Methods: A multicenter, retrospective observational cohort study with a cross-sectional PRO assessment was performed in adults with severe AA (SALT score ≥ 50) treated with baricitinib at 15 Spanish hospitals from June 2022 and with at least 36 weeks of follow-up, regardless of whether they remained on treatment. Sociodemographic, clinical, and treatment data were collected. Effectiveness was assessed using SALT score at treatment initiation and at 12, 24, 36, and 52 weeks, and the percentage of patients with SALT≤ 20. A cross-sectional visit (≥ 36 weeks since baricitinib initiation) collected the Treatment Satisfaction Questionnaire for Medication (TSQM), four ad-hoc questions regarding treatment satisfaction in specific areas (body hair, nails, beard, eyebrows/eyelashes), and the Scalp Hair Assessment PRO™. Analyses, all descriptive, summarized outcomes overall and by affected area, with persistence assessed via Kaplan-Meier. Results: 109 patients (67.9% females) were included in the study, with a mean (standard deviation [SD]) AA duration of 11.1 (11.0) years. The mean (SD) baseline SALT score was 81.1 (18.7) and 75.0% started with baricitinib monotherapy. At week 52, 91.8% continued treatment and 71.1% achieved a SALT≤ 20. Mean (SD) treatment satisfaction was 341.0 (51.4) out of 400 points on the TSQM. In subpopulations affected in specific areas, persistence rates exceeded 87%, at least 55% achieved SALT≤ 20 at week 52, and mean satisfaction score was above 320. Conclusion: In this real-world cohort in Spain, baricitinib use was associated with high treatment persistence and satisfaction, together with improved SALT scores in adults with severe AA, including those with involvement of body hair, nails, beard, and eyebrows/eyelashes. Plain Language Summary: Alopecia areata (AA) is a common autoimmune disease. It makes hair fall out in patches, without leaving scars. It affects men and women of all ages and often causes emotional distress and a lower quality of life. We studied 109 adults with severe AA who were treated with baricitinib, a tablet approved for this condition, at 15 hospitals in Spain. For every patient, at least 36 weeks had passed since starting baricitinib, whether or not they were still taking it when we collected the data. We measured how many patients stayed on treatment, how their hair regrew, and how satisfied they felt, at several points up to 52 weeks. By week 52, most patients were still taking baricitinib, and their scalp hair loss had improved significantly. Patients felt satisfied with the treatment, and almost 80% said their hair loss had improved. Even so, in everyday clinical practice, baricitinib use was associated with high treatment persistence, patient-reported satisfaction, and improvement in patients’ scalp hair loss scores and perception in adults with severe AA, including those with involvement of body hair, nails, beard, and eyebrows/eyelashes. These findings could help guide clinical decisions and improve the management of severe AA. Infographic summarizing population, methodology and findings for baricitinib in severe alopecia areata. Population: Adults with severe alopecia areata (AA) with SALT greater than or equal to 50, treated with baricitinib since June 2022 and with at least 36 weeks of follow-up. Methodology: Multicenter, retrospective observational cohort study with a cross-sectional PRO assessment conducted in 15 Spanish hospitals. A timeline shows a patient recruitment period from October 2024 to February 2025. The index date corresponded to baricitinib initiation. Retrospective data collection included AA diagnosis, previous AA treatments and clinical characteristics. Follow-up assessments, when available, were conducted at Weeks 12, 24, 36, and 52 and included sociodemographic and clinical characteristics, SALT, and AA treatment patterns. At the end of follow-up (greater than or equal to 36 weeks after baricitinib initiation), a cross-sectional assessment visit includes SALT and AA treatment patterns, together with patient-reported outcomes: TSQM, ad hoc treatment satisfaction in specific areas, and patient-reported scalp hair assessment. Findings: In Spanish routine clinical practice, baricitinib showed high treatment persistence (91.8 percent persistence at Week 52), effectiveness (71.1 percent achieved SALT less than or equal to 20 at Week 52), and high patient-reported satisfaction (341 out of 400 points on the TSQM) together with improved perceived scalp hair loss (78.5 percent reported improvement). These results were also observed in patients with involvement of special areas, including body hair, nails, beard hair, and eyebrows or eyelashes.Infographic on baricitinib for severe alopecia areata: population, methodology and findings.
- Open Access
- 7 June 2025
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 16 (1) , 1-18
Hair growth stimulated by allogenic adipose-derived stem cells supplemented with ATP in a mouse model of dihydrotestosterone-induced androgenetic alopecia
Androgenetic alopecia (AGA), also known as male or female pattern hair loss, is the most prevalent form of alopecia worldwide. Current treatments are based on hormone drugs, topical vasodilators and hair transplants. Newer options include stem cell therapy targeted at recovering the capacity for hair follicle regeneration. This study examines the effects of intradermally administering allogenic adipose-derived stem cells (ASCs) per se or supplemented with ATP in a mouse model of dihydrotestosterone (DHT)-induced AGA. Male and female C57BL6-strain mice were treated with DHT to induce AGA and then given injections of treatment solution in a defined area of the depilated back skin, and the same injections three days later. The treatments tested were several concentrations of ASCs combined with two ATP formulations. Photographs of the treated zones were taken on days 7, 10, 14, 17 and 21 and subjected to Image J analysis. On day 21, skin samples were also obtained for histological analysis. The main outcome measure was percentage treated surface area showing hair regrowth on treatment days 17 and 21 expressed as five categories: null, poor, moderate, intense and complete (20, 40, 60, 80 and 100% respectively). The experimental groups found to show the highest number of male individuals with intense/complete hair regrowth on day 21 were those in which mice received low dose ASCs (1 ∙ 106) combined either with liposomal ATP or non-liposomal ATP. Both these groups showed significant differences compared to controls. In females, while low dose ASC treatments and the high dose ASC + liposomal ATP treatment led to no hair regrowth improvement over the control treatment, medium dose ASC (2 × 106) + non-liposomal ATP gave rise to greater regrowth scores. Hair regrowth was improved in all experimental groups in which male mice were administered stem cell solutions supplemented with ATP. In female mice, the highest hair regrowth scores were observed for the medium dose ASC + liposomal ATP treatment.
- 7 June 2025
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 16 (1) , 1-18
Open AccessHair growth stimulated by allogenic adipose-derived stem cells supplemented with ATP in a mouse model of dihydrotestosterone-induced androgenetic alopecia
Androgenetic alopecia (AGA), also known as male or female pattern hair loss, is the most prevalent form of alopecia worldwide. Current treatments are based on hormone drugs, topical vasodilators and hair transplants. Newer options include stem cell therapy targeted at recovering the capacity for hair follicle regeneration. This study examines the effects of intradermally administering allogenic adipose-derived stem cells (ASCs) per se or supplemented with ATP in a mouse model of dihydrotestosterone (DHT)-induced AGA. Male and female C57BL6-strain mice were treated with DHT to induce AGA and then given injections of treatment solution in a defined area of the depilated back skin, and the same injections three days later. The treatments tested were several concentrations of ASCs combined with two ATP formulations. Photographs of the treated zones were taken on days 7, 10, 14, 17 and 21 and subjected to Image J analysis. On day 21, skin samples were also obtained for histological analysis. The main outcome measure was percentage treated surface area showing hair regrowth on treatment days 17 and 21 expressed as five categories: null, poor, moderate, intense and complete (20, 40, 60, 80 and 100% respectively). The experimental groups found to show the highest number of male individuals with intense/complete hair regrowth on day 21 were those in which mice received low dose ASCs (1 ∙ 106) combined either with liposomal ATP or non-liposomal ATP. Both these groups showed significant differences compared to controls. In females, while low dose ASC treatments and the high dose ASC + liposomal ATP treatment led to no hair regrowth improvement over the control treatment, medium dose ASC (2 × 106) + non-liposomal ATP gave rise to greater regrowth scores. Hair regrowth was improved in all experimental groups in which male mice were administered stem cell solutions supplemented with ATP. In female mice, the highest hair regrowth scores were observed for the medium dose ASC + liposomal ATP treatment.
- Open Access
- 1 December 2023
- Published by Elsevier in Nefrología (English Edition)
- Vol. 43, 114-116
Influenza vaccine-induced leukocytoclastic vasculitis in a patient with a transplanted kidney
- 1 December 2023
- Published by Elsevier in Nefrología (English Edition)
- Vol. 43, 114-116
Open AccessInfluenza vaccine-induced leukocytoclastic vasculitis in a patient with a transplanted kidney
- Open Access
- 1 September 2023
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 98 (5) , 696-698
Dermatologistas podem ser os primeiros a suspeitar de leiomiomatose hereditária e carcinoma de células renais
- 1 September 2023
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 98 (5) , 696-698
Open AccessDermatologistas podem ser os primeiros a suspeitar de leiomiomatose hereditária e carcinoma de células renais
- Open Access
- 23 May 2023
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 98 (5) , 696-698
Dermatologists might be the first to suspect hereditary leiomyomatosis and renal cell carcinoma syndrome
- 23 May 2023
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 98 (5) , 696-698
Open AccessDermatologists might be the first to suspect hereditary leiomyomatosis and renal cell carcinoma syndrome